High BCR-ABL/GUS-IS levels at diagnosis of chronic phase CML are associated with unfavorable responses to standard-dose imatinib - Vigneri, Paolo; Müller, Martin Christian (Clinical cancer research, 2017)
Published first September 19, 2017